A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial

William A. Gray(Main Line Health), Toshiaki Mano(Kansai Rosai Hospital), Steve Henao, Thomas Albrecht(Roche (Switzerland)), Christian Loewe(Medical University of Vienna), Andrew Benko(Centre Hospitalier Universitaire de Sherbrooke), Yazan Khatib, Sean Janzer, Jeffery T. Prem(Aultman Hospital), Robert Beasley, Daizo Kawasaki, Stewart Hawkins, Stefan Müller‐Hülsbeck(DIAKO), Safwan Jaalouk, William Bachinsky, Anvar Babaev(Columbia University Irving Medical Center), Robert Feldman, Patrick Hall, Daniel Dulas, Danielle Bajakian, Kenji Andò(Kokura Memorial Hospital), Michael Bacharach, Mark W. Fugate, Mark W. Burket, Michael R. Jaff(Boston Scientific (United States)), Juan Diaz‐Cartelle(Boston Scientific (United States)), Tony Das(Research Institute of Dallas), Koen Keirse, Andrew Holden(Auckland City Hospital), Jeffrey J. Popma(Cardiovascular Research Foundation), Jaafer Golzar, Benjamin J. Herdrich, Ethan C Korngold(Abbott (United Kingdom)), Hannes Deutschmann(Medical University of Graz), Rao Gutta, Keisuke Hirano, Yoshiaki Yokoi(Kishiwada Tokushukai Hospital), Randall De Martino, Henrik Schrøeder, James F. Benenati(Florida International University), Lawrence A. Garcia, Louis Lopez, Henry Lui, Kimihiko Kichikawa(Nara Medical University), Joseph Cardenas, Yoshimitsu Soga(Kokura Memorial Hospital)
The Lancet
September 24, 2018
Cited by 288


Related Papers